Management and Key personnel

 

  • Per Andersson

    CEO

    Per Andersson has been the CEO of Xspray Pharma AB since 2006. Per Andersson has extensive experience from the medical industry, especially within patent work and strategies. Previous positions include Science Director at Gyros AB and Scientist at GE Healthcare.

    Education: Ph.D. in Analytical Chemistry, Stockholm university

    Other current activities: Chariman of the board of Robotic Lawn Care Sweden AB and Deputy of Journeyman Stockholm AB

    Holdings: 115 403 shares and 154,857 warrants, where 69,857 warrants are cotingent of the listing of the company on First North.

    Independent in relation to the larger shareholders but not in relation to the company.

    Per Andersson has extensive experience from the medical industry. Previous positions include Science Director at Gyros AB and Scientist at GE Healthcare.

    +46 (0)8 730 37 00
  • Andreas Konar

    Business Development

    Background:
    Andreas Konar has 4 decades of experience from the pharmaceutical industry in R&D, clinical research, project management and business development. He has been VP R&D at Dumex and AL Pharma, responsible for the Drug Delivery Business Unit at LifeCycle Pharma, business development at Recordati and section manager at Astra Draco.

    Education: Associate Professor in Organic Chemistry, University of Lund, Sweden
    Ph.D. in Organic Chemistry, University of Lund, Sweden
    M.Sc. in Chemical Engineering, Chalmers University of Technology, Gothenburg, Sweden

    Other current assignments: Member of the Board of Ground Zero Pharmaceuticals, Irvine, CA, USA

    Holdings in the Company: 73 555 shares and 19 091 warrants

    Independent in relation to major shareholders but not in relation to the Company.

  • Charlotta Liljebris

    Research and Development

    Background:
    Charlotta Liljebris has 25 years of experience from the pharmaceutical industry. She has been responsible for the project portfolio and business development at Orexo, VP R&D at Aprea with focus on oncology and worked in several leading positions within project management at Biovitrum.

    Education: Ph.D. in Medicinal Chemistry, Uppsala University, Sweden
    M.Sc. in Chemistry, Uppsala University, Sweden

    Other current assignments: Member of the Board of Sprint Bioscience

    Other Board assignments (the rexent 5 years): Member of the Board of Recipharm OT Chemistry and Connect Uppsala

    Holdings in the Company: 1200 shares and 23 437 warrants

    Independent in relation to major shareholders but not in relation to the Company.

  • Kerstin Hasselgren

    CFO

    Background:
    Kerstin Hasselgren has broad experience from working in large public international companies as VP Corporate Business Control at SSAB, CFO at Alstom Transport Nordic, VP Finance Global Operations at AstraZeneca and VP Finance Global R&D at AstraZeneca

    Education: M.Sc. Business Administration, Stockholm School of Economics

    Other current assignments: None

    Other Board assignments (the recent 5 years): None

    Holdings in the Company: 4500 shares

    Independent in relation to major shareholders but not in relation to the Company.